Mark Swanson
Corporate Officer/Principal at Gel Med Sciences, Inc.
Profile
Mark Swanson is currently the Executive Vice President at Gel Med Sciences, Inc. He previously worked as the Vice President-Transgenic Sciences at DNX Transgenic Sciences and as a Senior Scientist at Sandoz Pharmaceuticals Corp.
Dr. Swanson obtained his doctorate degree from the University of Connecticut in 1983.
Mark Swanson active positions
| Companies | Position | Start |
|---|---|---|
Gel Med Sciences, Inc.
 Gel Med Sciences, Inc. Pharmaceuticals: MajorHealth Technology Gel Med Sciences, Inc. engages in the development of animal and human healthcare products. It offers ovugel that utilizes the company's gel drug delivery system to improve the timing of artificial inseminations in pig herds. The company was founded by Joseph S Duffey in 1999 and is headquartered in Wayne, PA. | Corporate Officer/Principal | - |
Former positions of Mark Swanson
| Companies | Position | End |
|---|---|---|
DNX Transgenic Sciences
 DNX Transgenic Sciences Miscellaneous Commercial ServicesCommercial Services Part of Revvity, Inc., DNX Transgenic Sciences is an American company that provides contract research services and transgenic animal technologies to the biomedical research community. The company is based in NJ. DNX Transgenic Sciences was acquired by Xenogen Corp., a subsidiary of Revvity, Inc. from Nordion (Canada), Inc. on November 13, 2000 for $35 million. | Corporate Officer/Principal | - |
| Sandoz Pharmaceuticals Corp. | Chief Tech/Sci/R&D Officer | - |
Training of Mark Swanson
| University of Connecticut | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 3 |
|---|---|
Gel Med Sciences, Inc.
Gel Med Sciences, Inc. Pharmaceuticals: MajorHealth Technology Gel Med Sciences, Inc. engages in the development of animal and human healthcare products. It offers ovugel that utilizes the company's gel drug delivery system to improve the timing of artificial inseminations in pig herds. The company was founded by Joseph S Duffey in 1999 and is headquartered in Wayne, PA. | Health Technology |
DNX Transgenic Sciences
DNX Transgenic Sciences Miscellaneous Commercial ServicesCommercial Services Part of Revvity, Inc., DNX Transgenic Sciences is an American company that provides contract research services and transgenic animal technologies to the biomedical research community. The company is based in NJ. DNX Transgenic Sciences was acquired by Xenogen Corp., a subsidiary of Revvity, Inc. from Nordion (Canada), Inc. on November 13, 2000 for $35 million. | Commercial Services |
| Sandoz Pharmaceuticals Corp. |
- Stock Market
- Insiders
- Mark Swanson
